Clinical trials have shown that Herceptin significantly improves survival rates and reduces the risk of cancer recurrence in HER2-positive breast cancer patients. When used in combination with chemotherapy, the benefits are even more pronounced. For metastatic cancers, Herceptin has been shown to prolong survival and improve the quality of life.
